SLC5A2 and prediabetes syndrome: Since SGLT-2 could exert systemic and cardiac anti-inflammatory effects in both preclinical and clinical trials, its use for prediabetes with DOXO-induced cardiotoxicity may be a promising cardioprotective strategy [28].